The Impact of Chemical Probes in Drug Discovery: A Pharmaceutical Industry Perspective

被引:54
|
作者
Garbaccio, Robert M. [1 ]
Parmee, Emma R. [1 ]
机构
[1] Merck Res Labs, Global Chem, Mailstop 14-2,740 Sumneytown Pike, West Point, PA 19486 USA
来源
CELL CHEMICAL BIOLOGY | 2016年 / 23卷 / 01期
关键词
SMALL-MOLECULE INHIBITORS; PEPTIDASE-IV INHIBITOR; RECEPTOR; TARGET; ANTAGONIST; POTENT; CELLS; AKT; REPLICATION; MK-0657;
D O I
10.1016/j.chembiol.2015.11.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chemical probes represent an important component of both academic and pharmaceutical drug discovery research. As a complement to prior reviews that have defined this scientific field, we aim to provide an industry perspective on the value of having high-quality chemical probes throughout the course of preclinical research. By studying examples from the internal Merck pipeline, we recognize that these probes require significant collaborative investment to realize their potential impact in clarifying the tractability and translation of a given therapeutic target. This perspective concludes with recommendations for chemical probe discovery aimed toward maximizing their potential to identify targets that result in the successful delivery of novel therapeutics.
引用
收藏
页码:10 / 17
页数:8
相关论文
共 50 条
  • [31] Physical Chemical Drug-Drug Interactions from Drug Discovery to Registration: New Opportunities for the Pharmaceutical Scientist To Impact Drug Development
    Ware, Joseph A.
    Dalziel, Gena
    MOLECULAR PHARMACEUTICS, 2013, 10 (11) : 3967 - 3969
  • [32] Opportunities and challenges in phenotypic drug discovery: an industry perspective
    Moffat, John G.
    Vincent, Fabien
    Lee, Jonathan A.
    Eder, Joerg
    Prunotto, Marco
    NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (08) : 531 - 543
  • [33] Transgenic animals and their impact on the drug discovery industry
    Dunn, DA
    Kooyman, DL
    Pinkert, CA
    DRUG DISCOVERY TODAY, 2005, 10 (11) : 757 - 767
  • [34] The CRISPR Revolution in the Drug Discovery Workflow: An Industry Perspective
    Lattanzi, Annalisa
    Maddalo, Danilo
    CRISPR JOURNAL, 2022, 5 (05): : 634 - 641
  • [35] Opportunities and challenges in phenotypic drug discovery: an industry perspective
    John G. Moffat
    Fabien Vincent
    Jonathan A. Lee
    Jörg Eder
    Marco Prunotto
    Nature Reviews Drug Discovery, 2017, 16 : 531 - 543
  • [36] Chemical Biology for Pharmaceutical Sciences (Novel Ideas for "Drug" Discovery)
    Sohma, Youhei
    Itoh, Yukihiro
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2017, 137 (03): : 281 - 282
  • [37] Role of population pharmacokinetics in drug development - A pharmaceutical industry perspective
    Samara, E
    Granneman, R
    CLINICAL PHARMACOKINETICS, 1997, 32 (04) : 294 - 312
  • [38] Role of Population Pharmacokinetics in Drug DevelopmentA Pharmaceutical Industry Perspective
    Emil Samara
    Richard Granneman
    Clinical Pharmacokinetics, 1997, 32 : 294 - 312
  • [39] Current Challenges in Drug Safety: A Perspective from the Pharmaceutical Industry
    Daniels, S.
    DRUG SAFETY, 2010, 33 (10) : 911 - 911
  • [40] Drug Discovery: Collaborations between Contract Research Organizations and the Pharmaceutical Industry
    Steadman, Victoria A.
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (07): : 581 - 583